Effects of DPP-4 inhibitors vs. sulfonylureas to metformin therapy in diabetes patients

Research has shown that dipeptidyl peptidase-4 (DPP-4) inhibitors provide glycemic control in patients with type 2 diabetes , but they also may increase the risk for heart failure. Researchers conducted a study to compare the clinical outcomes of adding DPP-4 inhibitors with sulfonylureas to metformin therapy.

Research has shown that dipeptidyl peptidase-4 (DPP-4) inhibitors provide glycemic control in patients with type 2 diabetes , but they also may increase the risk for heart failure. Researchers conducted a study to compare the clinical outcomes of adding DPP-4 inhibitors with sulfonylureas to metformin therapy. The study included patients with diabetes, who were aged 20 years or older in 2009–12. Researchers out of Taiwain examined 10,089 pairs of DPP-4 inhibitor users and sulfonylurea users. The study considered several outcomes: all-cause mortality, major adverse cardiovascular events (MACEs), hospitalization for heart failure, and hypoglycemia. Patients were followed until their death or year-end 2013. According to the results, DPP-4 inhibitors were associated with lower risks for all-cause death, MACEs, ischemic stroke, and hypoglycemia compared with sulfonylureas when used as an add-on therapy to metformin. The researchers note that DPP-4 inhibitors had no effect on the risks for myocardial infarction and hospitalization for heart failure, however.